Autolus Therapeutics (NASDAQ:AUTL) Trading Up 7.4% – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price rose 7.4% during trading on Wednesday . The stock traded as high as $1.93 and last traded at $1.97. Approximately 144,510 shares were traded during trading, a decline of 88% from the average daily volume of 1,187,248 shares. The stock had previously closed at $1.83.

Wall Street Analyst Weigh In

AUTL has been the topic of a number of analyst reports. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Trading Up 11.7 %

The business’s fifty day simple moving average is $2.15 and its two-hundred day simple moving average is $3.09. The stock has a market capitalization of $544.16 million, a P/E ratio of -1.69 and a beta of 2.07.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AUTL. Virtus ETF Advisers LLC raised its holdings in shares of Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after buying an additional 6,081 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after acquiring an additional 8,479 shares during the last quarter. Bellevue Group AG lifted its position in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the period. State Street Corp raised its position in shares of Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after acquiring an additional 10,866 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.